Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz

Journal of Clinical Pharmacology

Volumn 54, Issue 1, 2014, Pages 87-96

  Abdelhady, A M ^a   Desta, Z ^b   Jiang, F ^c   Yeo, C W ^c   Shin, J G ^c   Overholser, B R ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Inje University College of Medicine   (South Korea)

Author keywords

CYP2B6; Efavirenz; Metabolites; Pharmacogenomics; Pharmacokinetics

Indexed keywords

7 HYDROXYFAVIRENZ; 8 HYDROXYEFAVIRENZ; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; EFAVIRENZ; GENOMIC DNA; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; COMPARTMENT MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PHARMACOGENOMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

CYP2B6; EFAVIRENZ; METABOLITES; PHARMACOGENOMICS; PHARMACOKINETICS;

ADULT; ALGORITHMS; AREA UNDER CURVE; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DRUG INTERACTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PHARMACOGENETICS; POPULATION; REVERSE TRANSCRIPTASE INHIBITORS; TANDEM MASS SPECTROMETRY; TICLOPIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893316481     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.208     Document Type: Article

References (40)

1. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15(1):71-75
2. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;81(4):557-566
3. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73(1):20-30
4. Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit. 2004;26(3):267-270
5. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker ofCYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306(1):287-300
6. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo:identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos. 2010;38(7):1218-1229
7. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos. 2009;37(9):1793-1796
8. Mutlib AE, Chen H, Nemeth G, Gan LS, Christ DD. Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the nonnucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz. Drug Metab Dispos. 1999;27(9):1045-1056
9. Xu C, Ogburn ET, Guo Y, Desta Z. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab Dispos. 2012;40 (4):717-725
10. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007;8(6):547-558
11. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18(18):2391-2400
12. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenzcontaining regimens. Biochem Biophys Res Commun. 2004;319 (4):1322-1326
13. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. Polymorphic CYP2B6: molecularmechanisms and emerging clinical significance. Pharmacogenomics. 2007;8(7):743-759
14. Wyen C, Hendra H, Siccardi M, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother. 2011;66(9):2092-2098
15. Yimer G, Amogne W, Habtewold A, et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAARTinduced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J. 2012;12 (6):499-506
16. Desta Z, Kreutz Y, Nguyen AT, et al. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther. 2011;90(5):693-700
17. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics. 2009;19(4):300-309
18. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogeneticsbased population pharmacokinetic analysis of efavirenz in HIV-1- infected individuals. Clin Pharmacol Ther. 2009;85(5):485-494
19. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS. 2009;23(16):2101-2106
20. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIVinfected patients. Br J Clin Pharmacol. 2009;67(4):427-436
21. Ngaimisi E, Mugusi S, Minzi OM, et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther. 2010;88(5):676-684
22. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother. 2009;53(6):2346-2353
23. Nanzigu S, Eriksen J, Makumbi F, et al. Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIVinfected Ugandans. HIV Med. 2012;13(4):193-201
24. Viljoen M, Karlsson MO, Meyers TM, Gous H, Dandara C, Rheeders M. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. Eur J Clin Pharmacol. 2012;68(4):339-347
25. Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010;202(5):717-722
26. Winzer R, Langmann P, Zilly M, et al. No influence of the Pglycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res. 2003;8(12):531-534
27. Sanchez A, Cabrera S, Santos D, et al. Population pharmacokinetic/ pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother. 2011;55(11):5314-5324
28. Mukonzo JK, Roshammar D, Waako P, et al. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009;68(5):690-699
29. Cabrera SE, Santos D, Valverde MP, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009;53(7):2791-2798.
30. Jiang F, Desta Z, Shon JH, et al. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxylmetabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol. 2013;75(1):244-253
31. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007;45 (9):1230-1237
32. Cabrera Figueroa S, Iglesias Gomez A, Sanchez Martin A, de la Paz Valverde Merino M, Dominguez-Gil Hurle A, Cordero Sanchez M. Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. Clin Drug Investig. 2010;30(6):405-411
33. van Luin M, Gras L, Richter C, et al. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J Acquir Immune Defic Syndr. 2009;52 (2):240-245
34. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008;49(5):513-519
35. Mukonzo JK, Owen JS, Nanzigu S, et al. Population pharmacokinetic- pharmacogenetic efavirenz model among Ugandans. American Association of Pharmaceutical Sciences (annual meeting); 2012
36. Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE. 2011;6(12):e27810
37. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants. Pharmacogenet Genomics. 2012;22(12):858-867
38. Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol. 2012;68(3):267-271
39. Siccardi M, Almond L, Schipani A, et al. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin Pharmacol Ther. 2012;92 (4):494-502
40. Torno MS, Witt MD, Saitoh A, Fletcher CV. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. Pharmacotherapy. 2008;28(6):782-787